Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
Morten B Haulrig,1 Claus Zachariae,1,2 Lone Skov1,2 1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, DK-2900, Denmark; 2Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, DenmarkCorrespondence: Morten B HaulrigDepartment of De...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5915512e39f9488c99f0a299575a2fa6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Morten B Haulrig,1 Claus Zachariae,1,2 Lone Skov1,2 1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, DK-2900, Denmark; 2Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, DenmarkCorrespondence: Morten B HaulrigDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, DK-2900, DenmarkTel +45 38 67 31 32Fax +45 38 67 71 18Email Morten.bahrt.haulrig@regionh.dkAbstract: Psoriasis is a chronic inflammatory skin disease that affects up to 1.2% of children and adolescents. The treatment options for childhood psoriasis are often based on the same principles as in adults. However, most data on safety and efficacy derive from adult studies, and only a few of the frequently used treatments have achieved approval for use in children. The aim of this study was to review the current literature on off-label treatments for psoriasis in children and adolescents. We searched PubMed and identified 50 studies on off-label treatments. Of these, 23 studies were clinical trials (four randomized). There are only a small number of available studies on off-label treatments for children and adolescents with psoriasis, and many of these are retrospective reviews with few participants. Despite the current lack of studies, we still recommend the use of unapproved treatments since we have clinical experience with treatments such as topical corticosteroids, vitamin D analogs, and methotrexate that have shown promising effects. Regular clinical trials are needed to investigate the safety and efficacy of unapproved treatments. Due to The Pediatric Investigation Plans issued by The European Union, new drugs developed by pharmaceutical companies are required to undergo clinical trials in a pediatric population to get their application for marketing authorization processed. This will hopefully lead to much more data on the efficacy and safety of the new treatments, including treatments for children and adolescents with psoriasis.Keywords: psoriasis, unapproved treatment, childhood, adolescents |
|---|